5 clinical trials

Once the causes of hair loss appear (androgenetic alopecia, stress etc.) , excessive apoptosis provokes more hair to enter prematurely into the catagen phase (transition phase) and fall. As a consequence the anagen phase of hair (growing phase) becomes shorter.

The successive repetition of the premature onset of the catagen phase, caused by massive apoptosis, followed by shorter and shorter anagen phase leads to hair miniaturization (white, invisible, thin hair), called also male pattern baldness

In addition to a massive apoptosis phenomenon, excessive hair loss is also associated with scalp micro-inflammation.

Clinical trials in androgenetic alopecia subjects using CG 210™ have demonstrated the following benefits. In a published scalp biopsy trial performed on subjects with androgenetic alopecia, daily application of CG 210™ has enabled restoring back, in 3 months, an anti-apoptotic protein towards the level found in non alopecic subjects. Restoring the level of such anti-apoptotic protein should maintain more hair into the growing phase (anagen) and delay the premature transition of hair into the falling phase (catagen). Hair loss level may therefore not be excessive anymore, as long as the product is applied. CG 210™ has also enabled restoring back the level anti-inflammatory markers to a level considered normal. Restoring the level of such markers should enable control the micro-inflammation status associated with excessive hair loss. In a trial performed with the phototrycogram method on subjects with androgenetic alopecia, we have observed that the proportion of hair in the falling phase (telogen and catagen phases) started decreasing as early as 44 days after the start of CG 210™ application (2). After 3 months, the average number of new growing hair (hair in anagen phase) was above 8 200. In addition to being effective, CG 210™ is made from botanical ingredients, so is safe with no known side-effects.